Aerin Medical receives FDA clearance of next-gen RhinAe

Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of a next-generation RhinAer® stylus. RhinAer is a non-invasive, temperature-controlled radiofrequency technology that durably treats the causes of rhinorrhea (runny nose), post-nasal drip and congestion associated with chronic rhinitis in a single session. The new RhinAer is designed to provide physicians with improved visualization, easier access and tissue apposition, especially in patients with narrow nasal airways.

The new RhinAer stylus will be available for physicians to preview in the Aerin Medical booth at the American Rhinologic Society (ARS) annual meeting September 9-10, as well as at the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) annual meeting September 11-13. Both meetings will take place in Philadelphia.

“The new RhinAer stylus gives me confidence that I can access and treat the posterior nasal nerve area more effectively,” said Dr Randall Ow, otolaryngologist at Sutter Health in Sacramento and the first physician in the world to use the device on a patient. “This newer generation RhinAer allows me to confidently treat multiple target areas, in the office setting, even in very challenging anatomy.”

The new RhinAer is the result of close collaboration and feedback between Aerin Medical and otolaryngologists, with multiple enhancements intended to make the device easier to use. RhinAer’s new lower-profile stylus has been modified with a slimmer shaft and tip to improve visualization and access. Additionally, the tip now tilts backward 10 degrees, and the shaft is more malleable, which allows for easier tissue apposition during procedures.

“As a company that is committed to innovation, Aerin Medical relentlessly strives to meet the needs of physicians and their patients,” said Matt Brokaw, CEO of Aerin Medical. “We listened closely to the otolaryngology community in developing the new RhinAer. Based upon our discussions, rigorous testing and physician feedback, we are confident that the next-generation RhinAer stylus enhancements will be well-received.”

Rhinitis, or inflammation of the mucous membrane of the nose, can include symptoms such as runny nose, congestion, itching, sneezing, coughing, and post-nasal drip. Chronic rhinitis, when symptoms last more than four consecutive weeks, can be challenging to treat. With RhinAer, the stylus is inserted into the nasal airway to directly interrupt nerve signals and to help reduce chronic rhinitis symptoms. RhinAer has been clinically proven in multiple studies to durably treat chronic rhinitis symptoms. A recent long-term clinical study of RhinAer showed that 88.2% of patients positively responded to treatment at 24 months, defined as a ≥30% improvement in chronic rhinitis symptoms compared to baseline. Business Wire